Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.

[1]  T. Sio,et al.  Technical Note: Multiple energy extraction techniques for synchrotron-based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments. , 2021, Medical physics.

[2]  T. Sio,et al.  Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma. , 2021, Medical physics.

[3]  Tianming Liu,et al.  Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity-Modulated Proton Therapy (IMPT). , 2021, International journal of radiation oncology, biology, physics.

[4]  Joe Y. Chang,et al.  Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Jie Shan,et al.  Intensity-Modulated Proton Therapy (IMPT) Interplay Effect Evaluation of Asymmetric Breathing with Simultaneous Uncertainty Considerations in Patients with Non-Small Cell Lung Cancer. , 2020, Medical physics.

[6]  Sheng Huang,et al.  Technical Note: Integrating an open source Monte Carlo code "MCsquare" for clinical use in intensity-modulated proton therapy. , 2020, Medical physics.

[7]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[8]  S. Schild,et al.  Hybrid 3D analytical Linear Energy Transfer calculation algorithm based on pre-calculated data from Monte Carlo simulations. , 2019, Medical physics.

[9]  T. Sio,et al.  Technical Note: Treatment Planning System (TPS) Approximations Matter ─ Comparing Intensity Modulated Proton Therapy (IMPT) Plan Quality and Robustness between a Commercial and an In-house Developed TPS for Non-Small Cell Lung Cancer (NSCLC). , 2019, Medical physics.

[10]  Jie Shan,et al.  Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems , 2019, Technology in cancer research & treatment.

[11]  Wei Liu,et al.  A novel and individualized robust optimization method using normalized dose interval volume constraints (NDIVC) for intensity‐modulated proton radiotherapy , 2018, Medical physics.

[12]  T. Sio,et al.  Small‐spot intensity‐modulated proton therapy and volumetric‐modulated arc therapies for patients with locally advanced non‐small‐cell lung cancer: A dosimetric comparative study , 2018, Journal of applied clinical medical physics.

[13]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[14]  Wei Liu,et al.  Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. , 2018, International journal of radiation oncology, biology, physics.

[15]  Radhe Mohan,et al.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Wei Liu,et al.  Robust intensity‐modulated proton therapy to reduce high linear energy transfer in organs at risk , 2017, Medical physics.

[17]  H. Cohen,et al.  Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Joe Y. Chang,et al.  Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non–Small Cell Lung Cancer: Final Results of a Phase 2 Study , 2017, JAMA oncology.

[19]  Radhe Mohan,et al.  Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC , 2016, Radiation Oncology.

[20]  Wei Liu,et al.  Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. , 2016, International journal of radiation oncology, biology, physics.

[21]  I. Oh,et al.  Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation. , 2015, Japanese journal of clinical oncology.

[22]  Joe Y. Chang,et al.  Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  M. Berry,et al.  Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. , 2015, Lung cancer.

[24]  Wei Liu,et al.  Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. , 2015, Practical radiation oncology.

[25]  Y. Korogi,et al.  Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis , 2015, International Journal of Clinical Oncology.

[26]  Corinne Faivre-Finn,et al.  High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. , 2014, The Lancet. Oncology.

[27]  Wei Liu,et al.  Dosimetric benefits of robust treatment planning for intensity modulated proton therapy for base-of-skull cancers. , 2014, Practical radiation oncology.

[28]  Y. Korogi,et al.  Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. , 2013, Lung cancer.

[29]  Radhe Mohan,et al.  Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. , 2013, Medical physics.

[30]  Steven J Frank,et al.  PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. , 2013, Medical physics.

[31]  Wei Liu,et al.  Influence of robust optimization in intensity-modulated proton therapy with different dose delivery techniques. , 2012, Medical physics.

[32]  Radhe Mohan,et al.  Robust optimization of intensity modulated proton therapy. , 2012, Medical physics.

[33]  Benjamin Movsas,et al.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.

[34]  Joe Y. Chang,et al.  Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer , 2011, Cancer.

[35]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Govindan,et al.  Locally advanced non-small cell lung cancer: the past, present, and future. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[38]  Radhe Mohan,et al.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[39]  Mikael Karlsson,et al.  Number of patients potentially eligible for proton therapy , 2005, Acta oncologica.

[40]  J. Jett,et al.  The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Wei Liu,et al.  Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint , 2018, Medical physics.

[43]  W. Curran,et al.  National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer. , 2017, International journal of radiation oncology, biology, physics.

[44]  Wei Liu,et al.  Robust treatment planning with conditional value at risk chance constraints in intensity‐modulated proton therapy , 2017, Medical physics.

[45]  J. Galvin,et al.  Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.